Clinical Trial Update: Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated a triplet regimen of irinotecan, cisplatin, and bevacizumab in patients with unresectable or metastatic gastric or gastroesophageal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Diffuse Gastric Adenocarcinoma
• Gastric Cancer
• Intestinal Gastric Adenocarcinoma
• Mixed Gastric Adenocarcinoma
• Stage Iiia Gastric Cancer
• Stage Iiib Gastric Cancer
• Stage Iiic Gastric Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Cisplatin (Platinol) (cisplatin)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Phase 2 | Status: COMPLETED